BMS expects 9-13% decline in EPS after Plavix genericisation
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb expects its minimum projected non-GAAP EPS to be at least 9% lower in 2013 than its projected 2010 figure, as the loss of patent exclusivity to its lead product, the blood thinner Plavix (clopidogrel), takes full effect.